NXEN (Nexien BioPharma) Notes Receivable: $0.00 Mil (As of Mar. 2025)


What is Nexien BioPharma Notes Receivable?

Nexien BioPharma NXEN Notes Receivable is $0.00 Mil as of Mar. 2025.

Nexien BioPharma's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.

Nexien BioPharma Notes Receivable Related Terms

Nexien BioPharma Notes Receivable Historical Data

* Premium members only.

The historical data trend for Nexien BioPharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexien BioPharma Notes Receivable Chart

Nexien BioPharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Nexien BioPharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nexien BioPharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Nexien BioPharma (NXEN) has a Notes Receivable of $0.00 Mil as of Mar. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Nexien BioPharma and its competitors.
Is Nexien BioPharma's Notes Receivable too high?
Nexien BioPharma's current Notes Receivable is $0.00 Mil.
How does Nexien BioPharma's Notes Receivable compare to FLHLF and ZTS?
Nexien BioPharma's Notes Receivable of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Nexien BioPharma and its competitors. Nexien BioPharma's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexien BioPharma stock overvalued right now?
Nexien BioPharma (NXEN) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Nexien BioPharma (NXEN), the current Notes Receivable is $0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nexien BioPharma Business Description

Address 4340 East Kentucky Avenue, Suite 206, Glendale, CO, USA, 80246
Nexien BioPharma Inc is engaged in pre-clinical and drug development activities, by U.S. Food and Drug Administration (FDA) protocols, for certain pharmaceutical formulations that include cannabinoids. The company is pursuing the formulation and development of drugs containing cannabinoids for the treatment of various diseases, disorders, and medical conditions.